Class Action Appeal to 3rd Circuit on ERPOs Lack of Due Process Filed bearingarms.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bearingarms.com Daily Mail and Mail on Sunday newspapers.
Wednesday, April 14, 2021
Epic Games and Apple submit exhibit lists to U.S. court in preparation of May antitrust trial
Epic Games and Apple just submitted to the United States District Court for the Northern District of California their exhibit lists for next month s App Store antitrust trial. There are two lists per party: an exhibit list (text documents, such as emails), and an audiovisual exhibit list.
At the moment I don t have any particular comment, but with so many people being interested in the case, I just wanted to publish those lists here.
Epic s (non-audiovisual) exhibit list:
/PRNewswire/ The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States.
Share this article
Share this article
NEW YORK, April 14, 2021 /PRNewswire/ Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Lordstown Motors Corp. ( Lordstown or the Company ) (NASDAQ: RIDE) from August 3, 2020 through March 17, 2021 (the Class Period ). The lawsuit filed in the United States District Court for the Northern District of Ohio alleges violations of the Securities Exchange Act of 1934.
If you
purchased Lordstown securities, and/or would like to discuss your legal rights and options please visit Lordstown Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / April 14, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ( Intellipharmaceutics or the Company ), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2021. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
On July 2, 2020, the Company had announced that the parties in the cases, numbers 17-cv-392-RGA, 18-cv-404-RGA and 20-cv-515-RGA (the Litigations ) between Purdue Pharma L.P. et al ( Purdue ) and Intellipharmaceutics entered into a stipulated dismissal of the Litigations. The stipulated dismissal, which was subject to approval by the bankruptcy court presiding over Purdue Pharma s pending chapter